Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Cancer immunotherapy Stories

2010-08-10 07:00:00

SAN DIEGO, Aug. 10 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the follow-on Phase 2 grant award from the National Cancer Institute under the Small Business Technology Transfer Program (STTR). The grant is in the amount of $1,100,000 over the next two years subject to...

2010-07-22 07:00:00

SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma. The clinical trial will enroll 126 metastatic sarcoma...

2010-07-13 07:00:00

AMES, Iowa, July 13 /PRNewswire/ -- NewLink Genetics Corporation today announced that Joseph B. Saluri, J.D., has joined the company's board of directors, bringing more than a decade of experience in business development, legal and regulatory affairs, and collaborations and joint ventures. "Joe's knowledge and experience provide a valuable asset to the company as we seek new partners to collaborate on our HyperAcute immunotherapies for treating cancers and as we work to bring our novel...

2010-05-27 10:06:14

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer. Scancell Holdings plc, led by Professor Lindy Durrant of the University's Division of Clinical Oncology within the School of Molecular Medical Sciences, believes the new vaccine, which targets tumor cells without damaging healthy tissue, could be successful in treating patients with malignant melanoma. Incidences of...

676484de8f9b6501bc84d481dc30ad541
2010-05-22 08:37:44

Honeycombed particles filled with cancer drug act like time-release capsules at tumor site Packaging anti-cancer drugs into particles of chemically modified silica improve the drugs' ability to fight skin cancer in mice, according to new research. Results published May 3 in the Journal of the American Chemical Society online show the honeycombed particles can help anti-cancer antibodies prevent tumor growth and prolong the lives of mice. "We are very excited by our preliminary results," said...

2010-05-19 09:09:00

HACKENSACK, N.J., May 19 /PRNewswire/ -- A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug's safety and potential clinical action against advanced chronic lymphocytic leukemia (CLL). Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers. The drug did not demonstrate any...

2010-04-15 14:04:00

AMES, Iowa, April 15 /PRNewswire/ -- NewLink Genetics Corporation announced today that new data on its HyperAcute® lung cancer immunotherapy will be presented at a poster session at the 101st American Association for Cancer Research (AACR) Annual Meeting held April 17-21, 2010 in Washington, D.C. Data from the Phase I/II study titled "Phase I/II study of antitumor vaccination using lung cancer cells expressing murine alpha(1,3)galactosyltransferase (alphaGT) in non-small...

2010-04-06 08:30:00

TSX Venture: QPT EDMONTON, April 6 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has completed a critical review of the development status for its recently acquired therapeutic antibody platform, conducted in association with external consultants and leading international experts in cancer therapeutics and immunology. Advances in the...

2010-03-26 13:36:10

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumors are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference (EBCC7). Dr Marie Sundquist, from the Department of Surgery, County Hospital, Kalmar, Sweden, will say that the median survival times for five-year intervals of 557 metastatic breast...

2010-02-25 09:10:46

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors. The findings center on discovery of signaling molecules that are major players in a biochemical mechanism linking certain actions of B cells to solid tumor growth.  The most notable implication of the study is that a drug in use for more than decade to treat non-Hodgkin's lymphoma, which is a cancer of the B cells, might be effective against other...